LB PHARMACEUTICALS INC
LBRXNASDAQ🏆 #2340 by market capUS Equity
$37.29▼ $0.69 (−1.86%)
After hours · at closeTrack LBRX
Get earnings, price moves & breaking news on Telegram
24h▼ 1.9%
7d▼ 12.6%
14d▼ 13.3%
30d▼ 22.0%
ytd▲ 66.9%
1y▲ 145.1%
🏦Market Cap
$1.07B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $36.88 – $37.82
- 52-Week Range
- $13.36 – $50.16
- Volume
- $2.23B
- Avg Volume
- $2.86B
- Shares Outstanding
- 28.7M
- Next Earnings
- Dec 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $122M
- Last Q Revenue
- $27M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-2.98
- Dividend Yield
- —
- Dilution (1yr)
- +12.7%
Why Investors Own LBRX
- ✓High-growth profile — revenue up +27.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 50% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LB PHARMACEUTICALS INC
LBRXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▼ −53.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$35M▼ −34.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.3M▲ +12.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$247M▲ +$229M YoY
StockOtter · stockotter.spaceAbout LB PHARMACEUTICALS INC
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst Price Target
ⓘAverage Target
$37.19
▼ −0.2% Downside
High Target$41.80
Low Target$33.08
Based on 37 analysts
Latest News & Updates
🚀
Barron’s·2h ago
LB PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift LBRX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
LB PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.